Search Results
Jan 10, 2026, 10:00 ET RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. The encouraging anti-tumor activity,
More news about: Johnson & Johnson
Jan 10, 2026, 06:19 ET Pierre Fabre Laboratories e Iktos annunciano una collaborazione integrata per la scoperta di farmaci in oncologia basata sull'IA
polmonare non a piccole cellule (NSCLC) indotto dall'EGFR. È in fase di sperimentazione clinica PFL-002 su tumori solidi causati da alterazioni genetiche MET. È in fase di sviluppo exarafenib, un inibitore pan-RAF, per ampliare le opzioni terapeutiche mirate per i tumori solidi indotti da RAS/RAF. Inoltre,
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 22:30 ET Rain haalt $ 250 miljoen op in Series C-financieringsronde om de betalingsinfrastructuur die door stablecoin mogelijk wordt gemaakt op te schalen voor wereldwijde ondernemingen
Rain, de infrastructuur op bedrijfsniveau voor betalingen met stablecoin, heeft vandaag een Series C-financieringsronde van $ 250 miljoen aangekondigd onder leiding van ICONIQ, met deelname van Sapphire Ventures, Dragonfly, Bessemer Venture Partners, Galaxy Ventures, FirstMark,
More news about: Rain
Jan 09, 2026, 18:56 ET AB CarVal Grows Commercial Real Estate Private Credit Capabilities Through Multifamily and Residential Lending Partnerships
CarVal. "We believe that transitional lending on affordable U.S. housing – where population demographics have created higher demand currently not being met by U.S. supply – will continue to be a compelling private credit financing opportunity."Cedarline Lending specializes in senior-secured vertical
More news about: AB CarVal
Jan 09, 2026, 16:00 ET Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
6-month OS rate was 93%. Responses were observed across CLDN18.2 scores ≥ 10% (≥ 2+ staining). Of note, 85% of patients screened met this CLDN18.2 threshold requirement. Phanes' data of spevatamig featured at ASCO GI 2026 can be found here:
More news about: Phanes Therapeutics, Inc.
Jan 09, 2026, 13:00 ET Présentation d'ApexVision au salon CES (Consumer Electronics Show) 2026 : Guide Sensmart fait entrer l'imagerie thermique dans l'ère de l'ultranetteté
optiques d'extérieur pour la chasse (par exemple le monoculaire TD650LS et les jumelles TN650MS) bénéficient de la technologie Hyper-Light 2.0, qui met les utilisateurs en capacité de repérer la faune nocturne dans l'obscurité totale et de suivre des cibles qui se déplacent rapidement tout en conservant
More news about: Guide Sensmart
Jan 09, 2026, 10:54 ET Pierre Fabre Laboratories und Iktos kündigen eine integrierte KI-gestützte Zusammenarbeit bei der Arzneimittelentdeckung in der Onkologie an
entwickelt, der durch EGFR verursacht wird. PFL-002 befindet sich in der klinischen Erprobung bei soliden Tumoren, die durch genetische Veränderungen des MET verursacht werden. Der pan-RAF-Inhibitor Exarafenib wird entwickelt, um die Möglichkeiten der gezielten Therapie von RAS/RAF-gesteuerten soliden Tumoren
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 10:02 ET ITALIE, PROJETS SPÉCIAUX MONDIAUX DU SIGEP : À PARTIR DU 16 JANVIER À RIMINI, GELATO, PIZZA, HÔTELS DE LUXE ET BARS DU FUTUR
l'intégration de gelato artisanal, moelleux et glacé dans les menus mondiaux.La pizza sera présentée sur le site Pizza (R)evolution, qui met en valeur à la fois un produit emblématique et une plate-forme industrielle et commerciale. Un aperçu complet des ingrédients et des farines, des technologies,
More news about: Italian Exhibition Group
Jan 09, 2026, 10:00 ET Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
Pritesh J. Gandhi, Chief Development Officer, Partner Therapeutics. "Importantly, zenocutuzumab was able to maintain disease control even after patients met the conventional definition of progression—sometimes for years— without introducing new safety concerns."The data illustrate that several patients
More news about: Partner Therapeutics, Inc.
Jan 09, 2026, 06:08 ET Pierre Fabre Laboratories e Iktos se unen en el descubrimiento de fármacos en oncología basada en IA
células no pequeñas (CPCNP) inducido por EGFR. PFL-002 se encuentra en fase de pruebas clínicas en tumores sólidos inducidos por alteraciones genéticas MET. El inhibidor pan-RAF, exarafenib, se está desarrollando para ampliar las opciones de terapia dirigida para tumores sólidos inducidos por RAS/RAF. Además,
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 04:11 ET Hisense lance ses modèles 116UXS et XR10 au CES 2026 et fait passer la technologie RGB MiniLED dans une nouvelle dimension
l'innovation de nouvelle génération en matière de RGB MiniLED. En tant que sponsor officiel de la Coupe du monde 2026TM de la FIFA, Hisense met en place des partenariats sportifs mondiaux afin de nouer des liens avec des publics du monde entier.Photo -
More news about: Hisense
Jan 09, 2026, 02:00 ET Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology
developed for the treatment of EGFR-driven non-small cell lung cancer (NSCLC) patients. PFL-002 is undergoing clinical testing in solid tumors driven by MET genetic alterations. The pan-RAF inhibitor exarafenib is being developed to expand targeted therapy options for RAS/RAF-driven solid tumors. Moreover,
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 02:00 ET Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology
developed for the treatment of EGFR-driven non-small cell lung cancer (NSCLC) patients. PFL-002 is undergoing clinical testing in solid tumors driven by MET genetic alterations. The pan-RAF inhibitor exarafenib is being developed to expand targeted therapy options for RAS/RAF-driven solid tumors. Moreover,
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 02:00 ET Les Laboratoires Pierre Fabre et Iktos annoncent une collaboration basée sur l'intelligence artificielle intégrée dans le domaine de la recherche de médicaments contre le cancer
mutation de l'EGFR. Le PFL-002/VERT-002 fera l'objet d'essais cliniques pour les tumeurs solides induites par des altérations génétiques du récepteur MET. L'inhibiteur pan-RAF exarafenib est en cours de développement afin d'élargir les options de thérapie ciblée pour les tumeurs solides induites par RAS/RAF.
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 00:01 ET DOVE DEEPENS COMMITMENT TO MUSIC CULTURE WITH THE RETURN OF FAN-FIRST HOT SEATS PLATFORM AND ANNOUNCES OFFICIAL RECORDING ACADEMY® PARTNERSHIP FOR THE 2026 GRAMMY AWARDS®
sizzling prizes."Fan engagement is the ultimate cultural currency, and Hot Seats proved it in year one. We didn't just connect with fans; we met them where they were and brought to life music as a passion point for the brand," said Kevin Tolson, Head of Dove & SheaMoisture Deodorants at Unilever.
More news about: Dove
Jan 08, 2026, 19:00 ET MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
outside of China, once approved.This new agreement for YL201 builds on the successful collaboration initiated in January 2024 for the YL211 (c-Met ADC) program. MediLink and Roche are now deepening their collaboration through the development of YL201. Through this new agreement, the two companies
More news about: MediLink Therapeutics
Jan 08, 2026, 14:40 ET Mount St. Mary's Professor Philip Ravita and Ravita Jazz Earn 2026 Wammie Award Nominations for Acclaimed Album Alice Blue
Released in May 2025, Alice Blue has been met with strong critical response and commercial success, earning positive reviews and chart attention within the jazz community. The album showcases Ravita
More news about: Mount St. Mary's University
Jan 08, 2026, 14:00 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and Zepbound compared to Taltz monotherapy In a key secondary
More news about: Eli Lilly and Company
Jan 08, 2026, 11:06 ET Left Lane kondigt belangrijke partner- en VP-promoties aan en versterkt hun "Bevordering vanuit eigen gelederen" -cultuur
LaneLeft Lane, opgericht in 2019, is een wereldwijde onderneming in durf- en groeikapitaal die met duurzame klantrelaties in snelgroeiende consumenten- en internettechnologiebedrijven investeert. Met een klein, maar machtig team dat ongeveer $ 2,5 miljard aan activa beheert, is Left Lane opgezet om
More news about: Left Lane Capital
Jan 08, 2026, 11:01 ET Back Market Challenges America's Fast Tech Model at CES 2026 With "The Slow Tech Awakening"
fastest climate benefits available today. With circularity accounting for just 7 percent of the global economy, she argued that climate targets cannot be met without dramatically increasing repair, reuse, and refurbishment. "Extending the life of the devices we already have often delivers far greater climate
More news about: Back Market
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
patients with hypertension secondary to hypercortisolism." The press release stated that "[w]hile the FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint and that data from the company's GRADIENT trial provided confirmatory evidence, the Agency concluded it could not arrive at a favorable
More news about: Pomerantz LLP
Jan 08, 2026, 09:47 ET Envision Breaks into Brazil with 630MW Casa dos Ventos Project, Deploying AI-Driven Wind Power at Scale
Latin America."The agreement follows a series of high-level exchanges and strategic dialogues between the two companies. In May 2025, Lei Zhang met with Brazilian President Luiz Inácio Lula da Silva during the President's visit to China to discuss Brazil's green energy transition, net-zero industrial
More news about: Envision Energy
Jan 08, 2026, 09:28 ET Envision Breaks into Brazil with 630MW Casa dos Ventos Project, Deploying AI-Driven Wind Power at Scale
Latin America."The agreement follows a series of high-level exchanges and strategic dialogues between the two companies. In May 2025, Lei Zhang met with Brazilian President Luiz Inácio Lula da Silva during the President's visit to China to discuss Brazil's green energy transition, net-zero industrial
More news about: Envision Energy
Jan 08, 2026, 09:23 ET Sky Labs verkrijgt CE-MDR voor 'CART PLATFORM' en versnelt daarmee de toegang tot de wereldmarkt
het hele 'CART PLATFORM', gericht op het ringvormige medische apparaat dat uitgerust is met fotoplethysmografie (PPG) -sensoren, en omvat de mobiele app, server en de webviewer voor medische professionals.Met bloeddrukmeting als kern biedt het CART PLATFORM verschillende functies voor het monitoren
More news about: Sky Labs
Jan 08, 2026, 09:00 ET Chobani's Legacy Project Fund Expands to Four States
Philadelphia, the grant will support Lutheran Settlement House as it expands its vital work serving neighbors across the city. For more than a century, LSH has met urgent community needs while fostering connection, safety, and belonging. With its first three floors at max capacity, they will add an additional floor
More news about: Chobani, LLC